With no proven standard of care, Hodi et al. used gp100 as an active control for phase 3 study, which evaluated whether ipilimumab with or without gp100 improves overall survival, as compared with gp100 alone, among patients with metastatic melanoma [4]. This evidence concerns the gene PMEL and metastatic melanoma.